DONATE NOW

Cell and gene medicine can produce life-changing therapies for patients suffering from incurable diseases. The ARM Foundation for Cell and Gene Medicine is dedicated to providing the education, information, and research needed to accelerate patient awareness of and access to these transformative therapies.

The Foundation is an independent, 501(c)(3) non-profit organization established in 2018 by the Alliance for Regenerative Medicine (ARM), the preeminent international advocacy organization for regenerative medicine and advanced therapies.

Goal

The goal of the ARM Foundation for Cell and Gene Medicine is to educate, engage, and empower patients, caregivers, industry leaders, and other stakeholders to help advance the science and benefits of gene therapy, gene editing, cell therapy, tissue-engineering and organ regeneration. It will accomplish this through educational and research projects that increase public awareness of the clinical and social benefits of gene medicine, which will help to expedite the development of life-saving therapies.

Mission

The ARM Foundation serves as the educational and information resource on issues fundamental to making gene and cell therapies, tissue-engineered products and other regenerative medicine treatments available to patients.

By examining, quantifying, clarifying and informing stakeholders of the clinical and societal benefits of these therapies, as well as convening discussions to raise awareness about the sector’s progress, challenges and results, the Foundation accelerates patient access to safe, efficacious and potentially curative therapies.

 

LEADERSHIP

 

Board of Directors

 

Nicole Boice, CEO, Global Genes

Cindy Collins, CEO, Human Longevity

Amy Duross, CEO, Vineti

Don Gibbons, Former Head of Communications, CIRM; now comms consultant

Ellen Feigal, Partner, NDA Partners, former SVP R&D for CIRM

Alison Finger, SVP Marketing, bluebird bio

Karin Hehenberger, Founder & CEO, Lyfebulb; T1D Patient Organization;

Brett Kopelan, Executive Director, debra of America

Bethany Kraynack, VP Operations, ARM

Janet Lambert, CEO, ARM

Lin Mac Master, Former Chief Revenue Marketing & Communications Officer at the American Cancer Society, now independent comms consultant

Adrian McKemey, Managing Director Quintiles IQVIA, Founder, Quintiles Consulting

David Nagler, Formerly of Audentes

Stewart Parker, Former CEO, Targeted Genetics; Board Member Sangamo Therapeutics

Dennis Purcell, Founder, Senior Advisor, Aisling Partners

Brock Reeve, Executive Director, Harvard Stem Cell Institute

Martha Rook, Head of Gene Editing and Novel Modalities, MilliporeSigma

Morrie Ruffin, Executive Director, ARM Foundation

Frank Sasinowski, Director, Hyman, Phelps & McNamara

Robin Smith, Stem for Life Foundation and Cura Foundation

Jennifer Mound Smoter, SVP, External Affairs & Communications, Intellia Therapeutics

Marshall Summar, MD, National Children’s Medical Center; NORD Board Chair

Phil Vanek, General Manager, Cell Therapy, GE Healthcare Life Sciences

Claudia Zylberberg, CEO, Akron Biotech

 

ADMINISTRATIVE STAFF

 

Morrie Ruffin
Executive Director

Adam Roose
Advisor

Susan Sikora
Program Director

Erin Cummings
Executive Assistant



STEERING COMMITTEES

THIS IS PLACEHOLDER TEXT

The ARM Foundation for Cell and Gene Medicine relies on Steering Committees to guide vital program planning, implementation, and performance. Their role in creating value to all stakeholders is critical to the transformation of medicine, and we are grateful for their ongoing contributions.

 

INFRASTRUCTURE OF GENE AND CELL THERAPIES

 

Phil Vanek, PhD
General Manager, Cell Bioprocessing, GE Healthcare

Cindy Collins, MBA
Board of Directors, Triumvira Immunologics

Alison Finger, MBA
Chief Commercial Officer, Bluebird Bio

Amy Duross, MBA
Co-Founder and Chief Executive Officer, Vineti

Claudia Zylberberg
PhD, Co-Founder and Chief Executive Officer, Akron Biotech

Jerry Keybl
PhD, Head of Cell & Gene Therapy Manufacturing Franchise, MilliporeSigma

 

ECONOMIC IMPACT PROJECT

 

John Doyle, Dr.P.H., MPH
Senior Vice President and General Manager, Quintiles INQVIA

Peter Neumann, ScD
Director, Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center; Professor of Medicine, Tufts University School of Medicine

Eric Faulkner, MPH
Vice President and Executive Director, Real-World Value and Strategy, Center of Excellence for Precision and Transformative Technology, Evidera

Ron Bartek
President/Director/Co-Founder, FARA

Sean Tunis, MD, MSc
Founder and Chief Executive Officer, Center for Medical Technology Policy

David Smith, JD
Of Counsel, Pepper Hamilton, LLP

Scott Riccio, MBA
Head of Advocacy, Juno Therapeutics

Matthew Durdy
Chief Business Officer, Gene and Cell Therapy, UK Catapult

Dennis Purcell, MBA
Founder and Senior Advisor, Aisling Capital

Brock Reeve, MPhil, MBA
Executive Director, Harvard Stem Cell Institute

Jim Lennertz Jr.
Vice President and General Manager EUMEA, BioMarin

 

GENE MEDICINE EDUCATION PROGRAM

 

Max Bronstein
Senior Director, Health Policy & Public Affairs, Audentes (CO-CHAIR)

Francesa Cook
Director, Pricing & Access, REGENXBIO

Jill Dolgin
Head of Patient Advocacy, AGTC

Stephanie Fagan
SVP Corporate Communications, bluebird bio

Elisabeth Fine, PhD, CMPP
Director, Medical Affairs & Operations, Voyager Therapeutics

Maureen McArthur Hart, PhD
Strategic Advisor, Medical and Scientific Advisory Board, Global Genes

Tim Hunt
SVP, Corporate Affairs, Editas Medicine

Emily McGinnis
VP, Marketing, AveXis

Matt Might
Director, Hugh Kaul Precision Medicine Institute, Univ Alabama at Birmingham (CO-CHAIR)

Christeen Moburg
Sr. Director Patient Advocacy, Sangamo Therapeutics

Jennifer Mound Smoter
SVP, External Affairs & Communications, Intellia Therapeutics

Gary Surmay
Senior Director, US Public Affairs – Rare Disease, Pfizer